<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231213060357N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-04-11</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of Postsurgical Wound Healing, Pain and Complications of Plasma Pen-Assisted Surgery of Reactive Exophytic Oral Soft Tissue Lesions</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of Postsurgical Wound Healing, Pain and Complications of Plasma Pen-Assisted Surgery of Reactive Exophytic Oral Soft Tissue Lesions Compared to Conventional Surgery: A Randomized Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/82380</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The random allocation will be performed using a computer random number generator. For example, a random number (e.g., ۰ or ۱) will be generated. If the random number is ۰, the participant will be assigned to the control group ; if the random number is ۱, the participant will be assigned to the intervention group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Reactive Exophytic Oral Soft Tissue Lesions.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: After baseline examination and obtaining an informed consent, the lesions will be completely excised under local anesthesia using ۲% lidocaine with ۱:۱۰,۰۰۰ epinephrine using a plasma pen under perfectly aseptic conditions. Excision will be performed according to the standard oral surgical procedures. After retracting the basal part of the lesion superiorly using a clamp, excision will be performed such that the borders were in the intact tissue. It is important to note that the wounds occurred after the excisions with plasma pen will be allowed for secondary healing. Intervention 2: Control group: After baseline examination and obtaining an informed consent, the lesions will be completely excised under local anesthesia using ۲% lidocaine with ۱:۱۰,۰۰۰ epinephrine using a surgical blade under perfectly aseptic conditions. Excision will be performed according to the standard oral surgical procedures. After retracting the basal part of the lesion superiorly using a clamp, excision will be performed such that the borders were in the intact tissue.The incision will be closed by suture after bleeding has been controlled.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Data can be shared after de-identifying individuals.

When:
Data will be available up to 6 months after publication.

To whom:
The researchers in academic and scientific institutions

Conditions:
Data will be available after the trial is completed and results are published. This data can be used for research or educational purposes upon request, with a clear description of the intended use, and subject to approval by the study team and adherence to ethical research standards.

Where to obtain:
The data supporting the findings of this study will be available upon reasonable request from the corresponding author.

How to obtain:
The researchers in academic and scientific institutions can email the corresponding author and request for information.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Asma Sookhakian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shiraz University of Medical Sciences</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7195615878</zip>
        <telephone>+98 71 3628 0112</telephone>
        <email>asma.soukhakian@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Maryam Zahed</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shiraz School of Dentistry, Ghasrodasht street</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7195615878</zip>
        <telephone>+98 71 3628 0112</telephone>
        <email>maryamzhd@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>subjects (both males and females) aged ۱۸ years or older
Subjects diagnosed with reactive exophytic oral soft tissue lesions (less than one centimeter) on the buccal mucosa based on the clinical findings
Subjects who are willing to participate and complete this study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Any subject diagnosed clinically with possible neoplastic changes such as rapid growth pattern and induration
Any subject diagnosed with systemic diseases that could interfere with wound healing such as diabetes</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>D10</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Benign neoplasm of mouth and pharynx</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: After baseline examination and obtaining an informed consent, the lesions will be completely excised under local anesthesia using ۲% lidocaine with ۱:۱۰,۰۰۰ epinephrine using a plasma pen under perfectly aseptic conditions. Excision will be performed according to the standard oral surgical procedures. After retracting the basal part of the lesion superiorly using a clamp, excision will be performed such that the borders were in the intact tissue. It is important to note that the wounds occurred after the excisions with plasma pen will be allowed for secondary healing.</i_keyword>
      <i_keyword>Control group: After baseline examination and obtaining an informed consent, the lesions will be completely excised under local anesthesia using ۲% lidocaine with ۱:۱۰,۰۰۰ epinephrine using a surgical blade under perfectly aseptic conditions. Excision will be performed according to the standard oral surgical procedures. After retracting the basal part of the lesion superiorly using a clamp, excision will be performed such that the borders were in the intact tissue.The incision will be closed by suture after bleeding has been controlled.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain Level. Timepoint: 24 hours after the surgery, and  again after 2, 3, 4, 5, 6, and 7 days. Method of measurement: Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Wound Healing. Timepoint: On days 7, 14, 28, and 84 after surgery. Method of measurement: Wound healing index described by Landry et al, which evaluate parameters such as presence of bleeding, supporation, granulation tissue, tissue color, and  epithelialization.</prim_outcome>
      <prim_outcome>Complications. Timepoint: On days 7, 14, 28, and 84 after surgery. Method of measurement: Visual inspection to examine the surgery site for any visible changes such as redness, swelling, discoloration, scar, or recurrence, and palpation to assess for any palpable abnormalities.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-02-26</approval_date>
        <contact_name>Research Ethics Committee of School of Dentistry-Shiraz University of Medical Sciences</contact_name>
        <contact_address>Shiraz University of Medical Science, Zand street Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
